{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:31:51Z","timestamp":1792809111805,"version":"4.5.0"},"reference-count":120,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infectious Disease Clinics of North America"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.idc.2021.03.008","type":"journal-article","created":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T01:23:59Z","timestamp":1621301039000},"page":"415-434","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":232,"title":["Aspergillosis"],"prefix":"10.1016","volume":"35","author":[{"given":"Jose","family":"Cadena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"George R.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas F.","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.idc.2021.03.008_bib1","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1086\/525258","article-title":"Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America","volume":"46","author":"Walsh","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.idc.2021.03.008_bib2","doi-asserted-by":"crossref","first-page":"i5","DOI":"10.1093\/jac\/dkq437","article-title":"Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients","volume":"66","author":"Pagano","year":"2011","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"12","key":"10.1016\/j.idc.2021.03.008_bib3","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1086\/652761","article-title":"Geoclimatic influences on invasive aspergillosis after hematopoietic stem cell transplantation","volume":"50","author":"Panackal","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2021.03.008_bib4","series-title":"A\u00a0laboratory guide to common Aspergillus species and their teleomorphs","author":"Klich","year":"1988"},{"issue":"7228","key":"10.1016\/j.idc.2021.03.008_bib5","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nature07528","article-title":"Discovery of a sexual cycle in the opportunistic fungal pathogen Aspergillus fumigatus","volume":"457","author":"O'Gorman","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.idc.2021.03.008_bib6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3114\/sim.2007.59.08","article-title":"Nomenclatural considerations in naming species of Aspergillus and its teleomorphs","volume":"59","author":"Pitt","year":"2007","journal-title":"Stud Mycol"},{"issue":"4","key":"10.1016\/j.idc.2021.03.008_bib7","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/00005792-200007000-00006","article-title":"Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group","volume":"79","author":"Patterson","year":"2000","journal-title":"Medicine (Baltimore)."},{"issue":"5\u20136","key":"10.1016\/j.idc.2021.03.008_bib8","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s11046-014-9811-z","article-title":"Treatment of infections by cryptic Aspergillus species","volume":"178","author":"Nedel","year":"2014","journal-title":"Mycopathologia."},{"issue":"10","key":"10.1016\/j.idc.2021.03.008_bib9","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1128\/EC.00162-06","article-title":"Molecular studies reveal frequent misidentification of Aspergillus fumigatus by morphotyping","volume":"5","author":"Balajee","year":"2006","journal-title":"Eukaryot Cell."},{"issue":"10","key":"10.1016\/j.idc.2021.03.008_bib10","doi-asserted-by":"crossref","first-page":"4802","DOI":"10.1128\/AAC.00304-11","article-title":"Cryptic species and azole resistance in the Aspergillus niger complex","volume":"55","author":"Howard","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.idc.2021.03.008_bib11","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1086\/595846","article-title":"Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry","volume":"48","author":"Neofytos","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.idc.2021.03.008_bib12","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ccm.2009.03.001","article-title":"Fungal infections in hematopoietic stem cell transplantation and solid-organ transplantation\u2013focus on aspergillosis","volume":"30","author":"Nucci","year":"2009","journal-title":"Clin Chest Med"},{"issue":"23","key":"10.1016\/j.idc.2021.03.008_bib13","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1200\/JCO.2008.21.0856","article-title":"Index to predict invasive mold infection in high-risk neutropenic patients based on the area over the neutrophil curve","volume":"27","author":"Nucci","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.idc.2021.03.008_bib14","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1034\/j.1399-3062.2000.020105.x","article-title":"Investigation and control of aspergillosis and other filamentous fungal infections in solid organ transplant recipients","volume":"2","author":"Patterson","year":"2000","journal-title":"Transpl Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2021.03.008_bib15","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1128\/CMR.18.1.44-69.2005","article-title":"Aspergillus infections in transplant recipients","volume":"18","author":"Singh","year":"2005","journal-title":"Clin Microbiol Rev"},{"issue":"2","key":"10.1016\/j.idc.2021.03.008_bib16","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/00005792-199903000-00003","article-title":"Invasive aspergillosis in transplant recipients","volume":"78","author":"Paterson","year":"1999","journal-title":"Medicine"},{"issue":"6","key":"10.1016\/j.idc.2021.03.008_bib17","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1164\/rccm.2407004","article-title":"Aspergillosis in \"nonimmunocompromised\" critically ill patients","volume":"170","author":"Denning","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.idc.2021.03.008_bib18","doi-asserted-by":"crossref","first-page":"971","DOI":"10.3201\/eid1606.100165","article-title":"Invasive aspergillosis after pandemic (H1N1) 2009","volume":"16","author":"Lat","year":"2010","journal-title":"Emerg Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2021.03.008_bib19","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1164\/rccm.200401-093OC","article-title":"Invasive aspergillosis in critically ill patients without malignancy","volume":"170","author":"Meersseman","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.idc.2021.03.008_bib20","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/QCO.0000000000000043","article-title":"Approach to invasive pulmonary aspergillosis in critically ill patients","volume":"27","author":"Koulenti","year":"2014","journal-title":"Curr Opin Infect Dis"},{"issue":"Supplement_2","key":"10.1016\/j.idc.2021.03.008_bib21","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1093\/infdis\/jiz682","article-title":"Invasive Pulmonary Aspergillosis in Adults With Avian Influenza A (H7N9) Pneumonia in China: A Retrospective Study","volume":"221","author":"Zou","year":"2020","journal-title":"J\u00a0Infect Dis"},{"issue":"7","key":"10.1016\/j.idc.2021.03.008_bib22","doi-asserted-by":"crossref","first-page":"ofaa242","DOI":"10.1093\/ofid\/ofaa242","article-title":"Invasive Aspergillosis as an Under-recognized Superinfection in COVID-19","volume":"7","author":"Thompson Iii","year":"2020","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2021.03.008_bib23","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s12890-020-01257-w","article-title":"Invasive pulmonary aspergillosis in immunocompetent patients hospitalised with influenza A-related pneumonia: a multicenter retrospective study","volume":"20","author":"Chen","year":"2020","journal-title":"BMC Pulm Med"},{"issue":"10","key":"10.1016\/j.idc.2021.03.008_bib24","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S2213-2600(18)30274-1","article-title":"Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study","volume":"6","author":"Schauwvlieghe","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.idc.2021.03.008_bib25","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/j.chest.2020.06.010","article-title":"Influenza-Associated Aspergillosis: Nationwide Trends, Predictors and Outcomes From 2005 to 2014","volume":"158","author":"Sharma","year":"2020","journal-title":"Chest."},{"issue":"8","key":"10.1016\/j.idc.2021.03.008_bib26","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1007\/s00134-020-06091-6","article-title":"Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion","volume":"46","author":"Verweij","year":"2020","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.idc.2021.03.008_bib27","article-title":"Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM\/ISHAM consensus criteria for research and clinical guidance","author":"Koehler","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.idc.2021.03.008_bib28","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.idc.2020.02.010","article-title":"Fungal infections potentiated by biologics","volume":"34","author":"Davis","year":"2020","journal-title":"Infect Dis Clin North Am"},{"issue":"5","key":"10.1016\/j.idc.2021.03.008_bib29","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/infdis\/jiq102","article-title":"The Y238X stop codon polymorphism in the human beta-glucan receptor dectin-1 and susceptibility to invasive aspergillosis","volume":"203","author":"Chai","year":"2011","journal-title":"J\u00a0Infect Dis"},{"issue":"17","key":"10.1016\/j.idc.2021.03.008_bib30","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1056\/NEJMoa0802629","article-title":"Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation","volume":"359","author":"Bochud","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.idc.2021.03.008_bib31","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.idc.2015.10.015","article-title":"Invasive Aspergillosis: Current Strategies for Diagnosis and Management","volume":"30","author":"Cadena","year":"2016","journal-title":"Infect Dis Clin North Am"},{"issue":"Suppl 3","key":"10.1016\/j.idc.2021.03.008_bib32","doi-asserted-by":"crossref","first-page":"S265","DOI":"10.1086\/376526","article-title":"Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review","volume":"37","author":"Denning","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.idc.2021.03.008_bib33","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJM200003163421102","article-title":"A\u00a0randomized trial of itraconazole in allergic bronchopulmonary aspergillosis","volume":"342","author":"Stevens","year":"2000","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.idc.2021.03.008_bib34","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.jaip.2014.08.007","article-title":"Allergic bronchopulmonary aspergillosis","volume":"2","author":"Greenberger","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.idc.2021.03.008_bib35","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/00005792-198203000-00005","article-title":"Chronic necrotizing pulmonary aspergillosis: a discrete clinical entity","volume":"61","author":"Binder","year":"1982","journal-title":"Medicine"},{"issue":"2","key":"10.1016\/j.idc.2021.03.008_bib36","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1148\/radiology.140.2.7255704","article-title":"Semi-invasive\" pulmonary aspergillosis: a new look at the spectrum of aspergillus infections of the lung","volume":"140","author":"Gefter","year":"1981","journal-title":"Radiology"},{"issue":"Suppl 1","key":"10.1016\/j.idc.2021.03.008_bib37","doi-asserted-by":"crossref","first-page":"S207","DOI":"10.1080\/13693780400025179","article-title":"The invasive and saprophytic syndromes due to Aspergillus spp","volume":"43","author":"Hope","year":"2005","journal-title":"Med Mycol"},{"issue":"12","key":"10.1016\/j.idc.2021.03.008_bib38","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1086\/657306","article-title":"Efficacy and safety of posaconazole for chronic pulmonary aspergillosis","volume":"51","author":"Felton","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2021.03.008_bib39","doi-asserted-by":"crossref","first-page":"345","DOI":"10.7326\/0003-4819-100-3-345","article-title":"Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia","volume":"100","author":"Gerson","year":"1984","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.idc.2021.03.008_bib40","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1086\/516480","article-title":"Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation","volume":"175","author":"Wald","year":"1997","journal-title":"J\u00a0Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2021.03.008_bib41","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1055\/s-0031-1295715","article-title":"Pulmonary aspergillosis: recent advances","volume":"32","author":"Thompson","year":"2011","journal-title":"Semin Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.idc.2021.03.008_bib42","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1086\/513943","article-title":"Invasive aspergillosis","volume":"26","author":"Denning","year":"1998","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2021.03.008_bib43","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1200\/JCO.2001.19.1.253","article-title":"Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia","volume":"19","author":"Caillot","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.idc.2021.03.008_bib44","doi-asserted-by":"crossref","first-page":"S147","DOI":"10.1080\/13693780500064771","article-title":"The radiological spectrum of pulmonary aspergillosis","volume":"43","author":"Greene","year":"2005","journal-title":"Med Mycol"},{"issue":"1","key":"10.1016\/j.idc.2021.03.008_bib45","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/cncr.22738","article-title":"Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia: Proof of principle, description, and clinical and research implications","volume":"110","author":"Miceli","year":"2007","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.idc.2021.03.008_bib46","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1086\/652768","article-title":"Factors associated with mortality in transplant patients with invasive aspergillosis","volume":"50","author":"Baddley","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2021.03.008_bib47","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1159\/000196477","article-title":"Pulmonary aspergillosis: early diagnosis improves survival","volume":"62","author":"von Eiff","year":"1995","journal-title":"Respiration."},{"issue":"10","key":"10.1016\/j.idc.2021.03.008_bib48","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1056\/NEJM199103073241003","article-title":"Pulmonary aspergillosis in the acquired immunodeficiency syndrome","volume":"324","author":"Denning","year":"1991","journal-title":"N\u00a0Engl J Med"},{"issue":"3 Pt 1","key":"10.1016\/j.idc.2021.03.008_bib49","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1164\/ajrccm\/144.3_Pt_1.552","article-title":"Ulcerative tracheobronchitis after lung transplantation. A new form of invasive aspergillosis","volume":"144","author":"Kramer","year":"1991","journal-title":"Am Rev Respir Dis"},{"issue":"5","key":"10.1016\/j.idc.2021.03.008_bib50","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/MD.0b013e31826c2ccf","article-title":"Aspergillus tracheobronchitis: report of 8 cases and review of the literature","volume":"91","author":"Fernandez-Ruiz","year":"2012","journal-title":"Medicine (Baltimore)."},{"issue":"2","key":"10.1016\/j.idc.2021.03.008_bib51","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jaci.2011.11.039","article-title":"Fungal disease of the nose and paranasal sinuses","volume":"129","author":"Thompson","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.idc.2021.03.008_bib52","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s11882-012-0320-1","article-title":"Fungal disease of the nose and sinuses: an updated overview","volume":"13","author":"Chang","year":"2013","journal-title":"Curr Allergy Asthma Rep"},{"issue":"Suppl 1","key":"10.1016\/j.idc.2021.03.008_bib53","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.2500\/ajra.2013.27.3892","article-title":"Chapter 8: Invasive fungal rhinosinusitis","volume":"27","author":"Duggal","year":"2013","journal-title":"Am J Rhinol Allergy"},{"issue":"4","key":"10.1016\/j.idc.2021.03.008_bib54","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1001\/jamaophthalmol.2013.1497","article-title":"The mycotic ulcer treatment trial: a randomized trial comparing natamycin vs voriconazole","volume":"131","author":"Prajna","year":"2013","journal-title":"JAMA Ophthalmol"},{"issue":"6","key":"10.1016\/j.idc.2021.03.008_bib55","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/1469-0691.12389","article-title":"Osteomyelitis caused by Aspergillus species: a review of 310 reported cases","volume":"20","author":"Gabrielli","year":"2014","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"10.1016\/j.idc.2021.03.008_bib56","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016\u00a0Update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2021.03.008_bib57","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s15010-011-0108-6","article-title":"The efficacy of voriconazole in the treatment of 192 fungal central nervous system infections: a retrospective analysis","volume":"39","author":"Schwartz","year":"2011","journal-title":"Infection"},{"issue":"11","key":"10.1016\/j.idc.2021.03.008_bib58","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1086\/323900","article-title":"The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis","volume":"33","author":"Perfect","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2021.03.008_bib59","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/01.TP.0000044358.99414.B8","article-title":"The isolation of Aspergillus fumigatus from respiratory tract specimens in heart transplant recipients is highly predictive of invasive aspergillosis","volume":"75","author":"Munoz","year":"2003","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.idc.2021.03.008_bib60","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0002-9343(97)89455-7","article-title":"The use of respiratory-tract cultures in the diagnosis of invasive pulmonary aspergillosis","volume":"100","author":"Horvath","year":"1996","journal-title":"Am J Med"},{"issue":"6","key":"10.1016\/j.idc.2021.03.008_bib61","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.idc.2021.03.008_bib62","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1200\/JCO.2002.07.004","article-title":"Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients","volume":"20","author":"Herbrecht","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.idc.2021.03.008_bib63","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1182\/blood.V97.6.1604","article-title":"Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation","volume":"97","author":"Maertens","year":"2001","journal-title":"Blood."},{"issue":"Suppl","key":"10.1016\/j.idc.2021.03.008_bib64","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/13693780600904918","article-title":"Issues with galactomannan testing","volume":"44","author":"Verweij","year":"2006","journal-title":"Med Mycol"},{"issue":"12","key":"10.1016\/j.idc.2021.03.008_bib65","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1093\/cid\/ciu673","article-title":"Serum galactomannan-based early detection of invasive aspergillosis in hematology patients receiving effective antimold prophylaxis","volume":"59","author":"Duarte","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.idc.2021.03.008_bib66","doi-asserted-by":"crossref","first-page":"4879","DOI":"10.1128\/AAC.00673-10","article-title":"The initial 96 hours of invasive pulmonary aspergillosis: histopathology, comparative kinetics of galactomannan and (1->3) beta-d-glucan and consequences of delayed antifungal therapy","volume":"54","author":"Hope","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.idc.2021.03.008_bib67","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1128\/JCM.02281-09","article-title":"Prognostic features of galactomannan antigenemia in galactomannan-positive invasive aspergillosis","volume":"48","author":"Koo","year":"2010","journal-title":"J\u00a0Clin Microbiol"},{"issue":"1","key":"10.1016\/j.idc.2021.03.008_bib68","first-page":"9","article-title":"New concepts in diagnostics for invasive mycoses: non-culture-based methodologies","volume":"5","author":"Patterson","year":"2019","journal-title":"J\u00a0Fungi (Basel)"},{"key":"10.1016\/j.idc.2021.03.008_bib69","first-page":"1","article-title":"The aspergillus lateral flow assay for the diagnosis of invasive aspergillosis: an update","author":"Jenks","year":"2020","journal-title":"Curr Fungal Infect Rep"},{"issue":"2","key":"10.1016\/j.idc.2021.03.008_bib70","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1086\/421944","article-title":"Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome","volume":"39","author":"Odabasi","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"8941","key":"10.1016\/j.idc.2021.03.008_bib71","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0140-6736(95)91152-9","article-title":"Plasma (1-->3)-beta-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes","volume":"345","author":"Obayashi","year":"1995","journal-title":"Lancet."},{"issue":"9","key":"10.1016\/j.idc.2021.03.008_bib72","article-title":"Polymerase chain reaction blood tests for the diagnosis of invasive aspergillosis in immunocompromised people","author":"Cruciani","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"10.1016\/j.idc.2021.03.008_bib73","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/cid\/civ507","article-title":"Aspergillus Polymerase Chain Reaction: Systematic Review of Evidence for Clinical Use in Comparison With Antigen Testing","volume":"61","author":"White","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.idc.2021.03.008_bib74","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1128\/JCM.00667-15","article-title":"Analytical and Clinical Evaluation of the PathoNostics AsperGenius Assay for Detection of Invasive Aspergillosis and Resistance to Azole Antifungal Drugs during Testing of Serum Samples","volume":"53","author":"White","year":"2015","journal-title":"J\u00a0Clin Microbiol"},{"issue":"12","key":"10.1016\/j.idc.2021.03.008_bib75","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/cid\/ciu725","article-title":"A\u00a0breath fungal secondary metabolite signature to diagnose invasive aspergillosis","volume":"59","author":"Koo","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2021.03.008_bib76","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/QCO.0000000000000203","article-title":"What's new in antifungals: an update on the in-vitro activity and in-vivo efficacy of new and investigational antifungal agents","volume":"28","author":"Wiederhold","year":"2015","journal-title":"Curr Opin Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2021.03.008_bib77","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.idc.2021.03.008_bib78","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1093\/cid\/ciu911","volume":"60","author":"Herbrecht","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2021.03.008_bib79","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1517\/17425250903463878","article-title":"Pharmacology and clinical use of voriconazole","volume":"6","author":"Thompson","year":"2010","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"5","key":"10.1016\/j.idc.2021.03.008_bib80","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/jac\/dkt508","article-title":"Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology","volume":"69","author":"Ashbee","year":"2014","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"8","key":"10.1016\/j.idc.2021.03.008_bib81","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/cid\/cis599","article-title":"The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial","volume":"55","author":"Park","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2021.03.008_bib82","first-page":"93","article-title":"Impact of intravenous administration of voriconazole in critically ill patients with impaired renal function","volume":"20","author":"Alvarez-Lerma","year":"2008","journal-title":"J\u00a0Chemother"},{"issue":"4","key":"10.1016\/j.idc.2021.03.008_bib83","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.idc.2021.03.008_bib84","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease","volume":"356","author":"Ullmann","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.idc.2021.03.008_bib85","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1086\/508774","article-title":"Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial","volume":"44","author":"Walsh","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2021.03.008_bib86","unstructured":"Maertens J, Rahav G, Lee DG, Ponce De Leon A. Efficacy and Safety of Posaconazole versus Voriconazole for the Treatment of Invasive Aspergillosis. European Congress of Clinical Microbiology and Infectious Diseases 2020. 2020;Oral Presentation."},{"issue":"5","key":"10.1016\/j.idc.2021.03.008_bib87","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1128\/AAC.00240-09","article-title":"Posaconazole therapeutic drug monitoring: a reference laboratory experience","volume":"53","author":"Thompson","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.idc.2021.03.008_bib88","doi-asserted-by":"crossref","first-page":"6993","DOI":"10.1128\/AAC.04035-14","article-title":"Switching from posaconazole suspension to tablets increases serum drug levels in leukemia patients without clinically relevant hepatotoxicity","volume":"58","author":"Jung","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.idc.2021.03.008_bib89","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00188-17","article-title":"Real-life assessment of the safety and effectiveness of the new tablet and intravenous formulations of posaconazole in the prophylaxis of invasive fungal infections via analysis of 343 courses","volume":"61","author":"Tverdek","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.idc.2021.03.008_bib90","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s40265-020-01306-y","article-title":"Pharmacokinetics and Pharmacodynamics of Posaconazole","volume":"80","author":"Chen","year":"2020","journal-title":"Drugs."},{"issue":"12","key":"10.1016\/j.idc.2021.03.008_bib91","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1093\/cid\/ciz741","article-title":"Posaconazole serum drug levels associated with pseudohyperaldosteronism","volume":"70","author":"Nguyen","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.idc.2021.03.008_bib92","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1093\/jac\/dkaa366","article-title":"Management of posaconazole-induced pseudohyperaldosteronism","volume":"75","author":"Davis","year":"2020","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"12","key":"10.1016\/j.idc.2021.03.008_bib93","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01723-18","article-title":"Effects of food and omeprazole on a novel formulation of super bioavailability itraconazole in healthy subjects","volume":"62","author":"Lindsay","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.idc.2021.03.008_bib94","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00400-20","article-title":"Open-label crossover oral bioequivalence pharmacokinetics comparison for a 3-day loading dose regimen and 15-day steady-state administration of SUBA-itraconazole and conventional itraconazole capsules in healthy adults","volume":"64","author":"Thompson","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"10.1016\/j.idc.2021.03.008_bib95","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2165\/00003495-200161001-00003","article-title":"Pharmacology of itraconazole","volume":"61","author":"De Beule","year":"2001","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.idc.2021.03.008_bib96","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/myc.12749","article-title":"Itraconazole induced hypertension and hypokalemia: Mechanistic evaluation","volume":"61","author":"Hoffmann","year":"2018","journal-title":"Mycoses."},{"issue":"1","key":"10.1016\/j.idc.2021.03.008_bib97","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1128\/AAC.00705-08","article-title":"Antifungal therapeutic drug monitoring: established and emerging indications","volume":"53","author":"Andes","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.idc.2021.03.008_bib98","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11046-010-9324-3","article-title":"Isavuconazole: a comprehensive review of spectrum of activity of a new triazole","volume":"170","author":"Thompson","year":"2010","journal-title":"Mycopathologia."},{"issue":"10020","key":"10.1016\/j.idc.2021.03.008_bib99","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet."},{"issue":"10","key":"10.1016\/j.idc.2021.03.008_bib100","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/cid\/civ571","article-title":"Isavuconazole: a new broad-spectrum triazole antifungal agent","volume":"61","author":"Miceli","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2021.03.008_bib101","first-page":"79","article-title":"Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infections","volume":"9","author":"Donnelley","year":"2016","journal-title":"Infect Drug Resist"},{"issue":"5","key":"10.1016\/j.idc.2021.03.008_bib102","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/mmy\/myz083","article-title":"Ibrexafungerp: A novel oral glucan synthase inhibitor","volume":"58","author":"Davis","year":"2020","journal-title":"Med Mycol"},{"issue":"11","key":"10.1016\/j.idc.2021.03.008_bib103","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1056\/NEJMct060052","article-title":"Echinocandins for candidemia in adults without neutropenia","volume":"355","author":"Bennett","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.idc.2021.03.008_bib104","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1093\/jac\/dkp355","article-title":"An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients","volume":"64","author":"Viscoli","year":"2009","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.idc.2021.03.008_bib105","first-page":"410","article-title":"Intravenous micafungin versus voriconazole for chronic pulmonary aspergillosis: a multicenter trial in Japan","volume":"61","author":"Kohno","year":"2010","journal-title":"J\u00a0Infect"},{"issue":"5","key":"10.1016\/j.idc.2021.03.008_bib106","first-page":"337","article-title":"Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis","volume":"53","author":"Denning","year":"2006","journal-title":"J\u00a0Infect"},{"issue":"11","key":"10.1016\/j.idc.2021.03.008_bib107","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1007\/s10096-010-1013-0","article-title":"Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort","volume":"29","author":"Hiemenz","year":"2010","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2021.03.008_bib108","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1399-3062.2008.00349.x","article-title":"Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis","volume":"11","author":"Kontoyiannis","year":"2009","journal-title":"Transplant Infect Dis"},{"issue":"10","key":"10.1016\/j.idc.2021.03.008_bib109","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1086\/497126","article-title":"Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome","volume":"41","author":"Patterson","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.idc.2021.03.008_bib110","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1086\/319211","article-title":"Mortality and costs of acute renal failure associated with amphotericin B therapy","volume":"32","author":"Bates","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.idc.2021.03.008_bib111","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1086\/514341","article-title":"Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)","volume":"44","author":"Cornely","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.idc.2021.03.008_bib112","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/M13-2508","article-title":"Combination antifungal therapy for invasive aspergillosis: a randomized trial","volume":"162","author":"Marr","year":"2015","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.idc.2021.03.008_bib113","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3201\/eid2106.140717","article-title":"Prospective multicenter international surveillance of azole resistance in Aspergillus fumigatus","volume":"21","author":"van der Linden","year":"2015","journal-title":"Emerg Infect Dis"},{"issue":"4","key":"10.1016\/j.idc.2021.03.008_bib114","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/QCO.0000000000000662","article-title":"Aspergillus fumigatus and pan-azole resistance: who should be concerned?","volume":"33","author":"Wiederhold","year":"2020","journal-title":"Curr Opin Infect Dis"},{"issue":"9","key":"10.1016\/j.idc.2021.03.008_bib115","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/myc.12960","article-title":"Defining breakthrough invasive fungal infection-Position paper of the mycoses study group education and research consortium and the European Confederation of Medical Mycology","volume":"62","author":"Cornely","year":"2019","journal-title":"Mycoses."},{"issue":"4","key":"10.1016\/j.idc.2021.03.008_bib116","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.bbmt.2010.04.017","article-title":"Efficacy, safety, and breakthrough infections associated with standard long-term posaconazole antifungal prophylaxis in allogeneic stem cell transplantation recipients","volume":"17","author":"Winston","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.idc.2021.03.008_bib117","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1111\/myc.13148","article-title":"Breakthrough invasive fungal infections: Who is at risk?","volume":"63","author":"Jenks","year":"2020","journal-title":"Mycoses."},{"issue":"4","key":"10.1016\/j.idc.2021.03.008_bib118","first-page":"216","article-title":"Diagnosis of Breakthrough Fungal Infections in the Clinical Mycology Laboratory: An ECMM Consensus Statement","volume":"6","author":"Jenks","year":"2020","journal-title":"J\u00a0Fungi (Basel)"},{"issue":"11","key":"10.1016\/j.idc.2021.03.008_bib119","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/myc.12213","article-title":"Our 2014 approach to breakthrough invasive fungal infections","volume":"57","author":"Maschmeyer","year":"2014","journal-title":"Mycoses."},{"issue":"1","key":"10.1016\/j.idc.2021.03.008_bib120","first-page":"28","article-title":"Aspiring antifungals: review of current antifungal pipeline developments","volume":"6","author":"Gintjee","year":"2020","journal-title":"J\u00a0Fungi (Basel)"}],"container-title":["Infectious Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552021000180?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552021000180?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:30:57Z","timestamp":1760196657000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0891552021000180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":120,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S0891552021000180"],"URL":"https:\/\/doi.org\/10.1016\/j.idc.2021.03.008","relation":{},"ISSN":["0891-5520"],"issn-type":[{"value":"0891-5520","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aspergillosis","name":"articletitle","label":"Article Title"},{"value":"Infectious Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idc.2021.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}